Financial Statements

Alexion Pharmaceuticals, Inc. (ALXN)


0.00 (0.00%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands

Retained Earning Schedule

Year 2020 2019 2018 2017 2016
Retained Earnings (Previous Year) 4,6402,3262,2421,818-
Net Income 6032,40478443399
Stock Dividends --906-191,419
Dividend Paid -----
Retained Earnings 5,2434,6402,3262,2421,818

PPE Schedule

Year 2020 2019 2018 2017 2016
Gross PPE 1,1631,4711,3251,036-
Annual Depreciation 406-1373596461,369
Capital Expenditure -107-171-213-357-333
Net PPE 1,4621,1631,4711,3251,036

Intangible and Goodwill Schedule

Year 2020 2019 2018 2017 2016
Intangible and Goodwill (Previous Year) -5,0375,0375,0375,037
New Purchases -675-1,659-805-171-77
Intangible and Goodwill 5,0375,0375,0375,0375,100

Alexion Pharmaceuticals, Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Alexion Pharmaceuticals, Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.